Europe's Committee for Human Medicinal Products (CHMP) has recommended reinstating the echocardiography indication for Bracco's SonoVue ultrasound contrast agent.
SonoVue's echocardiography indication was temporarily suspended on May 21 as a precautionary measure in agreement with the European Agency for the Evaluation of Medicinal Products (EMEA). CHMP recommended that the reinstatement of SonoVue be accompanied by an extension of contraindications to patients with recent acute coronary symptoms or clinically unstable ischemic cardiac disease, according to Bracco.
By AuntMinnie.com staff writersAugust 5, 2004
Related Reading
Bracco clarifies SonoVue restrictions, May 24, 2004
EMEA restricts use of SonoVue, May 20, 2004
Bracco sets up new facility in Italy, May 4, 2004
Bracco forms Chinese joint venture, April 5, 2004
Bracco adds Christus Health, April 5, 2004
Copyright © 2004 AuntMinnie.com